MCRB - Seres Therapeutics, Inc.
| Previous Close | 3.6800 |
| Open | 3.6600 |
| Bid | 3.6000 x 900 |
| Ask | 3.6100 x 800 |
| Day's Range | 3.4900 - 3.6600 |
| 52 Week Range | 2.0200 - 9.0000 |
| Volume | 163,302 |
| Avg. Volume | 536,921 |
| Market Cap | 251.688M |
| Beta (3Y Monthly) | 2.45 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.8660 |
| Earnings Date | Mar 6, 2019 - Mar 11, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 9.86 |
- Zacks
Seres Therapeutics, Inc. (MCRB) Shares March Higher, Can It Continue?
As of late, it has definitely been a great time to be an investor in Seres Therapeutics, Inc. (MCRB).
- Thomson Reuters StreetEvents
Edited Transcript of MCRB earnings conference call or presentation 6-Aug-19 12:00pm GMT
Q2 2019 Seres Therapeutics Inc Earnings Call
- American City Business Journals
Microbiome biotechs grapple with how to protect their IP
Microbiome companies face an added complication that other drugmakers may not when trying to maintain an exclusive hold on their products: It’s not possible to patent a naturally occurring substance like plants or bacteria.
Motley FoolSeres Therapeutics Inc (MCRB) Q2 2019 Earnings Call Transcript
MCRB earnings call for the period ending June 30, 2019.
- Zacks
Seres Therapeutics (MCRB) Reports Q2 Loss, Tops Revenue Estimates
Seres Therapeutics (MCRB) delivered earnings and revenue surprises of 42.86% and 21.78%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- Business Wire
Seres Therapeutics Appoints Stephen Berenson to its Board of Directors
Mr. Berenson is a Managing Partner at Flagship Pioneering and previously spent his career as an investment banker at J.P. Morgan. “Flagship Pioneering continues to view the microbiome as a rapidly emerging and highly promising field with vast therapeutic potential.
- Business Wire
Seres Therapeutics Reports Second Quarter Financial Results and Provides Progress Update
- Four significant microbiome program milestones expected during 2020, including readouts from two late-stage development programs –
- ACCESSWIRE
Seres Therapeutics, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / August 6, 2019 / Seres Therapeutics, Inc. (NASDAQ: MCRB ) will be discussing their earnings results in their 2019 Second Quarter Earnings to be held on August 6, 2019 at 8:00 ...
- Zacks
Seres Therapeutics (MCRB) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
Seres Therapeutics (MCRB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Simply Wall St.
Do Directors Own Seres Therapeutics, Inc. (NASDAQ:MCRB) Shares?
Every investor in Seres Therapeutics, Inc. (NASDAQ:MCRB) should be aware of the most powerful shareholder groups...
- Simply Wall St.
What Kind Of Shareholders Own Seres Therapeutics, Inc. (NASDAQ:MCRB)?
The big shareholder groups in Seres Therapeutics, Inc. (NASDAQ:MCRB) have power over the company. Insiders often own a...
- Business Wire
Seres Therapeutics Issues Statement Regarding U.S. Food and Drug Administration Safety Alert Related to Use of Fecal Microbiota Transplantation
FDA alert does not impact Seres’ microbiome investigational therapeutic candidates
- PR Newswire
Microbiome Therapeutics Innovation Group Statement on FDA Safety Alert Regarding Use of Fecal Microbiota for Transplantation and Risk of Serious Adverse Reactions Due to Transmission of Multi-Drug Resistant Organisms
WASHINGTON , June 17, 2019 /PRNewswire/ -- On June 13, 2019 , the U.S. Food and Drug Administration (FDA) issued a safety alert regarding the use of fecal microbiota for transplantation, or FMT: https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/important-safety-alert-regarding-use-fecal-microbiota-transplantation-and-risk-serious-adverse ...
- Business Wire
Seres Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock
Seres Therapeutics, Inc. (MCRB) (“Seres”), a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, today announced the pricing of an underwritten public offering of 26,666,667 shares of its common stock, at a public offering price of $2.25 per share, before underwriting discounts and commissions. Seres also granted the underwriters a 30-day option to purchase up to an additional 2,666,666 shares of its common stock. Goldman Sachs & Co. LLC and Cowen and Company, LLC are acting as joint book-running managers for the offering.
- Benzinga
The Daily Biotech Pulse: Savara Slumps On Flunked Trial, NuCana Takes Off, Tetraphase Downsizes
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 12) BIOFRONTERA AG/ADR (NASDAQ: BFRA ) BIO-TECHNE Corp ...
- Business Wire
Seres Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
Seres Therapeutics, Inc. (MCRB) (“Seres”), a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, today announced that it is commencing an underwritten registered public offering of $60.0 million of shares of its common stock. As part of this offering, Seres intends to grant the underwriters a 30-day option to purchase up to an additional $9.0 million of shares of its common stock. Goldman Sachs & Co. LLC and Cowen and Company, LLC are acting as joint book-running managers for the offering.
- Business Wire
Seres Therapeutics to Present at the Jefferies 2019 Healthcare Conference
A live audio webcast of the presentation will be available under the “Investors and Media” section of Seres’ website. Seres Therapeutics, Inc. (MCRB) is a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, where the state of bacterial diversity and function is imbalanced. Seres is also developing SER-401 in a Phase 1b study in patients with metastatic melanoma.
- Thomson Reuters StreetEvents
Edited Transcript of MCRB earnings conference call or presentation 2-May-19 12:30pm GMT
Q1 2019 Seres Therapeutics Inc Earnings Call
- Zacks
Seres Therapeutics (MCRB) Reports Q1 Loss, Lags Revenue Estimates
Seres Therapeutics (MCRB) delivered earnings and revenue surprises of -27.91% and -15.00%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press
Seres Therapeutics: 1Q Earnings Snapshot
On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of 59 cents. Losses, adjusted for restructuring costs, came to 55 cents per share. The results did not meet Wall Street ...
- Business Wire
Seres Therapeutics Reports First Quarter Financial Results and Provides Clinical Pipeline Progress Update
- Four significant microbiome program milestones expected during 2020, including readouts from two late-stage development programs –
- Business Wire
Seres Therapeutics to Host First Quarter 2019 Financial Results and Operational Progress Conference Call and Webcast on May 2, 2019
To access the conference call, please dial 844-277-9450 (domestic) or 336-525-7139 (international) and reference the conference ID number 3368968. Seres Therapeutics, Inc. (MCRB) is a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, where the state of bacterial diversity and function is imbalanced. Seres’ SER-287 program has obtained Orphan Drug designation from the U.S. Food and Drug Administration and is being evaluated in a Phase 2b study in patients with active mild-to-moderate ulcerative colitis.
- Investor's Business Daily
Gut Check: The Bacteria In Your Intestines Could Help Cure Cancer
Big Pharma is rapidly increasing its investments into biotech companies aiming to treat disease by targeting the microbiome. Some are also working on using bacterial strains as drugs.
- Business Wire
Seres Therapeutics Presents New Preclinical Data Supporting the Development of SER-401 for Immuno-Oncology at the 2019 American Association for Cancer Research Annual Meeting
“The novel data presented at AACR provide mechanistic insights into the biological activity of our microbiome therapeutic candidates to augment immune checkpoint inhibitors,” said Matthew Henn, Ph.D., Chief Scientific Officer and Executive Vice President at Seres. Seres presented preclinical results evaluating the impact of various consortia of bacterial species on the anti-tumor immune response in murine models following treatment with an anti-PD-1 checkpoint inhibitor.
